1 / 23

Intussusception Following Use of RotaShield , A Summary

Intussusception Following Use of RotaShield , A Summary . Hector S. Izurieta Vaccine Safety Branch Division of Epidemiology Office of Biostatistics and Epidemiology. Clinical trials. Findings of pre-licensure clinical trials:

nhung
Télécharger la présentation

Intussusception Following Use of RotaShield , A Summary

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Intussusception Following Use of RotaShield, A Summary Hector S. Izurieta Vaccine Safety Branch Division of Epidemiology Office of Biostatistics and Epidemiology

  2. Clinical trials • Findings of pre-licensure clinical trials: • In multiple trials, a total of 5 intussusception (IT) cases were found in 10,054 vaccinees (0.05%) vs. 1 case in 4,633 controls (0.02%) • Difference not statistically significant • All 5 cases occurred after second or third dose • Two occurred with the final vaccine formulation

  3. Licensure of RotaShield • Package insert • IT described as potential adverse reaction • August 31, 1998, licensure of RotaShield • FDA/CDC monitor passive reporting of IT to Vaccine Adverse event reporting System (VAERS) • Post licensure phase 4 study planned • March, 1999, ACIP recommended RotaShield for routine use

  4. Recommendation for Routine Use Suspended (MMWR, July 1999) • 15 IT cases in VAERS (11 during first week). • Expected number for first week based on doses administered: 14-16 • Population-based studies find high (non-significant) rates of IT within one week following vaccination • ranging between 292 and 314 cases per 100,000 • MMWR stimulates VAERS reporting

  5. Withdrawal of RotaShield • October 15, 1999: Wyeth voluntarily withdraws RotaShield • Decision based in part on preliminary results from CDC’s Case Control and Case series studies • October 22, 1999: ACIP withdraws recommendation for vaccine use • License revoked, November 15, 2002

  6. Main Study Results • Case-control study and case series analysis find significant results* • Observational cohort (VSD) study also finds significant results** • The effect of age at vaccination is being debated# * Murphy et al.., N Engl J Med. 2001 ** Kramarz et al., Pediatr Infect Dis J. 2001 # Simonsen et al, 2005; Paul Gargiullo, CDC, unpublished

  7. Population Attributable Risk for IT • Studies differed in methodology, strengths and limitations • Consensus estimate of population attributable risk* : • 1 IT case per 10,000 vaccinees • high estimate=1 per 5,000 • low estimate=1 per 12,000 * Peter G and Myers M. Pediatrics, 2002

  8. Evidence of Possible Association With Natural Rotavirus Infection • Lack of clear evidence that natural rotavirus infection causes IT* • Rotavirus infection associated with increased distal ileum wall thickness and lymphadenopathy** * Rennels et al, Pediatrics, 1998 ** Robinson et al, JID 2004

  9. Possible Mechanisms for Association Between RotaShield and IT • RotaShield contains a simian (strain RRV) backbone • “Unique strain” hypothesis* • RRV shed predominantly after first dose • RRV might be evading recognition by passively acquired specific antibodies * Paul Offit, personal communication

  10. Summary • Evidence indicates existence of causal association between RotaShield and IT • Association identified post-licensure • Precise mechanisms debated • Consensus estimate of population attributable risk* ~1 per 10,000 vaccinees * Peter G and Myers M. Pediatrics, 2002

  11. Acknowledgements Miles Braun, OBE/CBER/FDA Robert Ball, OBE/CBER/FDA Mary Foulkes, OBE/CBER/FDA Douglas Pratt, OVRR/CBER/FDA Paul Gargiulo, NIP/CDC Trudy Murphy, NIP/CDC

  12. Outline of Pharmacovigilance Plans for Rotateq® Hector S. Izurieta VSB/DE/OBE/CBER/FDA

  13. Justification • Both FDA and CDC are committed to ensure the safety of all vaccines • Rotateq is a live vaccine • Evidence of an association between a prior rotavirus vaccine (Rotashield) and intussusception • The association was confirmed after licensure

  14. Pharmacovigilance for Rotateq®:Main Resources • Main government resources • Vaccine Adverse Events Reporting System (VAERS) • Vaccine Safety Datalink (VSD) Project • Sponsor’s role (Pharmacovigilance plan ) • Accelerated reporting of adverse events to FDA • Reports could be sent in monthly batches • Phase 4 study • Other

  15. Vaccine Adverse Events Reporting System (VAERS) (1) • National passive surveillance system for reporting vaccine adverse events • Co-managed by FDA and CDC • Voluntary, easy to report • Nationwide reach • Useful for signal detection

  16. VAERS (2) • VAERS will receive accelerated reporting by Sponsor • Daily review of all serious reports and of • Confirmed and suspected intussusception (IT) • Gastrointestinal symptoms

  17. VAERS, Main Limitations • Absence of denominator data • Underreporting • Missing/wrong data • Usually, causality cannot be established

  18. Vaccine Safety Datalink (VSD) • Collaboration between CDC and Health Maintenance Organizations (HMOs) • As needed, feedback from FDA • Approximately 8 million members (4% of U.S. population) • Birth cohort ~96,000

  19. VSD, Main Characteristics • Large, well defined populations • Computerized linkable databases • Initial plan under development contemplates working with automated data • Chart reviews available, if needed • Can determine strength of an association

  20. VSD, Potential Limitation • Full uptake of a new vaccine by HMOs could take a few years • Many years could be required to detect increased risk of a rare event • Alternatively, participation of additional HMOs may be needed

  21. Considerations on Sponsor’s Phase 4 study • Clinical trials • large (~35,000 vaccinees) • population studied does not necessarily represent those who will use the vaccine after licensure • Proposed Phase 4 study has sample size of ~25,000 vaccinees

  22. Sponsor’s Phase 4 Study: Location • Location, a VSD site? • If so: • Overlap with Government-sponsored study? • Duplication of efforts? • CDC-FDA-Sponsor conference to discuss plans?

  23. Acknowledgements Miles Braun, CBER/FDA Robert Ball, CBER/FDA Douglas Pratt, CBER/FDA Rose Tiernan, CBER/FDA Frank Destefano, CDC Penina Haber, CDC

More Related